Analyzing Vor Biopharma (NASDAQ:VOR) and Liminatus Pharma (NASDAQ:LIMN)

Liminatus Pharma (NASDAQ:LIMN) and Vor Biopharma (NASDAQ:VOR) are both small-cap manufacturing companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, dividends, valuation and profitability.

Profitability

This table compares Liminatus Pharma and Vor Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	N/A
Vor Biopharma	N/A	N/A	N/A

Institutional and Insider Ownership

97.3% of Vor Biopharma shares are owned by institutional investors. 0.5% of Vor Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Liminatus Pharma and Vor Biopharma”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liminatus Pharma	N/A	N/A	N/A	($0.05)	-21.40
Vor Biopharma	N/A	N/A	N/A	($386.83)	-0.03

Liminatus Pharma is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Liminatus Pharma and Vor Biopharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1	0	0	0	1.00
Vor Biopharma	1	4	5	1	2.55

Vor Biopharma has a consensus target price of $73.17, suggesting a potential upside of 630.94%. Given Vor Biopharma’s stronger consensus rating and higher probable upside, analysts clearly believe Vor Biopharma is more favorable than Liminatus Pharma.

Summary

Vor Biopharma beats Liminatus Pharma on 7 of the 8 factors compared between the two stocks.

About Liminatus Pharma

Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.

About Vor Biopharma

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company’s eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.